BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21436635)

  • 1. Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay.
    Chae BJ; Bae JS; Yim HW; Lee A; Song BJ; Jeon HM; Chun MH; Jung SS
    Pathology; 2011 Apr; 43(3):248-53. PubMed ID: 21436635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.
    Tas F
    Onkologie; 2012; 35(3):95-8. PubMed ID: 22414972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of immunohistochemistry assays and real-time reverse transcription-polymerase chain reaction for analyzing hormone receptor status in human breast carcinoma.
    Oda M; Arihiro K; Kataoka T; Osaki A; Asahara T; Ohdan H
    Pathol Int; 2010 Apr; 60(4):305-15. PubMed ID: 20403033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases.
    Ree AH; Florenes VA; Berg JP; Maelandsmo GM; Nesland JM; Fodstad O
    Clin Cancer Res; 1997 Sep; 3(9):1623-8. PubMed ID: 9815852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.
    Badve SS; Baehner FL; Gray RP; Childs BH; Maddala T; Liu ML; Rowley SC; Shak S; Perez EA; Shulman LJ; Martino S; Davidson NE; Sledge GW; Goldstein LJ; Sparano JA
    J Clin Oncol; 2008 May; 26(15):2473-81. PubMed ID: 18487567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oestrogen and progesterone receptors in Nigerian breast cancer: relationship to tumour histopathology and survival of patients.
    Ikpatt OF; Ndoma-Egba R
    Cent Afr J Med; 2003; 49(11-12):122-6. PubMed ID: 15301464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel tumor suppressor gene RhoBTB2 (DBC2): frequent loss of expression in sporadic breast cancer.
    Mao H; Qu X; Yang Y; Zuo W; Bi Y; Zhou C; Yin H; Deng B; Sun J; Zhang L
    Mol Carcinog; 2010 Mar; 49(3):283-9. PubMed ID: 19937980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progesterone receptor B (PRB) promoter hypermethylation in sporadic breast cancer: progesterone receptor B hypermethylation in breast cancer.
    Mc Cormack O; Chung WY; Fitzpatrick P; Cooke F; Flynn B; Harrison M; Fox E; Gallagher E; McGoldrick A; Dervan PA; McCann A; Kerin MJ
    Breast Cancer Res Treat; 2008 Sep; 111(1):45-53. PubMed ID: 17896177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
    Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
    Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated preoperative serum ICTP is a prognostic factor for overall and disease-free survival in breast cancer.
    Keskikuru R; Bloigu R; Risteli J; Kataja V; Jukkola A
    Oncol Rep; 2002; 9(6):1323-7. PubMed ID: 12375042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer.
    Climent J; Martinez-Climent JA; Blesa D; Garcia-Barchino MJ; Saez R; Sánchez-Izquierdo D; Azagra P; Lluch A; Garcia-Conde J
    Clin Cancer Res; 2002 Dec; 8(12):3863-9. PubMed ID: 12473601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The prognostic value of cathepsin D concentration in cytosol of primary breast carcinoma].
    Bussen S; Rempen A; Caffier H
    Zentralbl Gynakol; 1995; 117(5):253-9. PubMed ID: 7793167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma.
    Davis LM; Harris C; Tang L; Doherty P; Hraber P; Sakai Y; Bocklage T; Doeden K; Hall B; Alsobrook J; Rabinowitz I; Williams TM; Hozier J
    J Mol Diagn; 2007 Jul; 9(3):327-36. PubMed ID: 17591932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
    Francis G; Beadle G; Thomas S; Mengersen K; Stein S
    Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunohistochemical investigation of steroid hormones (ER, PR) in breast cancer].
    Mchedlishvili MIu; Gabunia UA; Makharoblidze ER; Burnadze KT; Piradashvili DZ
    Georgian Med News; 2005 Feb; (119):65-7. PubMed ID: 15834186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and mutational analysis of GATA3 in Malaysian breast carcinomas.
    Bong PN; Zakaria Z; Muhammad R; Abdullah N; Ibrahim N; Emran NA; Syed Hussain SN
    Malays J Pathol; 2010 Dec; 32(2):117-22. PubMed ID: 21329183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.